Women's Heart Advisor April 2015 Issue

FDA Approves New Blood Test for People without Heart Disease

FDA Approves New Blood Test for People without Heart Disease

Testing for Lp-PLA2 levels may help predict an individual’s risk of developing cardiovascular disease and the likely outcome following a heart attack.

Most heart attacks occur when fatty plaques in the arteries rupture, spilling their contents into the bloodstream. This process, which is caused by inflammation, triggers the release of an enzyme called lipoprotein-associated phospholipase A2 , or Lp-PLA2. The higher the level of Lp-PLA2 in the blood, the greater the risk of stroke, first or recurrent heart attack or poor outcome after a heart attack. It can also predict increased risk of cardiovascular disease in people with insulin sensitivity/pre-diabetes is part of metabolic syndrome, but they’re not synonymous.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.